• Must possess a doctoral degree (or equivalent).
• Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training).

• Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
• PIs must have a designated mentor who is an experienced prostate cancer researcher.
• Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI�s career development is required.

• Maximum funding of $300,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years.

• In the last year of an accredited medical residency or medical fellowship program
or
• Within 5 years of having initiated a faculty appointment (including Instructor positions).

• Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
• PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
• PIs must have a designated mentor with an established research program in prostate cancer.
• Applications are strongly encouraged to demonstrate protection of at least 40% of the PI�s time for prostate cancer research (not required to be exclusive to this award).
• Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI�s career development is required.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

• Supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY21 PCRP Overarching Challenges.
• Translational research may be defined as an integration of basic science and clinical observations, including a reciprocal flow of ideas and information from bench to beside and/or bedside to bench.
• Supports a broad range of translational studies such as:
  • Advanced translation of results from animal studies to applications with human samples/cohorts.
  • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission.
  • Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trial to inform future work.
  • Projects that develop endpoints for clinical trials.
• Preliminary data to support the feasibility of the research hypotheses and research approaches are required. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.
• Clinical trials are not allowed.
• Each PI may submit only one application.
• Partnering PI Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. Collaborations between basic science and clinical researchers are highly encouraged.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

• Have the freedom to pursue individual aims without formal mentorship.
• Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award.
• Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave).

• Supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality.
• Proposed projects must address one of the following health disparity focus areas: (1) access to healthcare, (2) social and cultural factors, (3) environmental factors, or (4) biological and genetic contributors.
• Proposed projects may include basic, translational, population science, or clinical research, including clinical trials.
• Primary emphasis will be placed on the potential impact of the proposed work.
• Preliminary data are encouraged, but not required.
• Each PI may submit only one application.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

• Have the freedom to pursue individual aims without formal mentorship.
• Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award.
• Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family medical leave).

• Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY21 PCRP Overarching Challenges.
• Emphasis is equally placed on Innovation and Impact.
• Preliminary data are encouraged, but not required.
• Clinical trials are not allowed.
• Each PI may submit only one application.
• Multidisciplinary projects are encouraged, and multi-institutional projects are allowed.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

• Supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data.
• Applications may propose development of a new data-science driven tool or apply an existing tool or method to gather and analyze information from large data sets with the intent of advancing prostate cancer research and patient care relative to the FY21 PCRP Overarching Challenges.
• Research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas, as they pertain to prostate cancer:
• Computational Biology
• Bioinformatics
• Artificial Intelligence and machine learning
• Epidemiology
• Analysis of -omics data
• Imaging Assessments
• Digital Pathology Assessments
• Analysis of clinically annotated datasets
• Clinical research is allowed, but must be retrospective; prospective recruitment of human subjects and/or collection of clinical data, images, samples, etc. is not allowed.
• Presentation of preliminary data is strongly encouraged, but not required.
• Partnering PI Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. Collaborations between data scientists and clinicians are highly encouraged. At least one of the submitting or partnering PIs must have expertise in prostate cancer basic and/or clinical research.

• Maximum funding of $1,000,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

• Supports collaborations incorporating innovative and translational approaches that have the potential to make a major impact on one of the following FY21 PCRP Overarching Challenges:
• Advancing health equity and reducing disparities in prostate cancer.
• Improving quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer.
• The consortium requires a synergistic, multidisciplinary team of leading scientists, clinicians, and consumer advocates that will address the PCRP Overarching Challenge from multiple perspectives in a way that could not be accomplished by a single investigator or group.
  • Scientists and/or clinicians who have specific expertise related to health disparities or survivorship research or other areas of expertise related to addressing the overarching theme of the proposal should be included.
  • Teams are encouraged to also include promising early-career investigators and scientists from nontraditional disciplines.
  • At least one prostate cancer consumer advocate must be included on each research team; this person should have an active role in every aspect of the proposed consortium�s work.
• The consortium must include one Consortium Director and three or more additional Research Teams; a minimum of three institutions must be represented.
• Consortia funding will be offered in two phases. Phase 1 awardees will be eligible to compete for phase 2 funding in FY23, pending availability of funds.

• Provides initial support necessary to establish the infrastructure of the consortium and to conduct one or more pilot studies.
• Pilot studies are expected to serve as the basis for future consortium projects by generating preliminary data and providing proof of concept for the studies that will be proposed for phase 2 funding.
• Clinical trials are not allowed.

• Only recipients of a phase 1 Consortium Research Award will be eligible for phase 2 funding support.
• Proposed translational projects should build on the results of the phase 1 pilot study (or studies) and should include multiple, parallel projects that approach the research problem from a variety of perspectives.
• Continued phase 2 funding may be contingent upon successful completion of specific research milestones and goals.

• Maximum funding of $2,700,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years.

• Maximum funding of $10,000,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

• Supports a consortium will facilitate the rapid execution of collaborative phase 2 or phase 1/2 clinical trials that will bring to market high-impact, novel therapeutic interventions that will significantly decrease the impact of prostate cancer.
• One Coordinating Center and 10 Clinical Research Sites will be selected and will be jointly responsible for proposing, selecting, and conducting trials.
• Funds may not be used for research or development of clinical protocols.
• Significant emphasis is placed on the inclusion of patients from diverse populations, particularly those from high-risk (e.g., men of African descent, Caribbean Americans), underserved (e.g., men with limited access to clinical care and resources in rural or urban settings), and/or military populations (Service members and Veterans).
• Coordinating Center applications will identify two or more Affiliate Clinical Research Sites to be supported and managed by the Coordinating Center that must specialize in the recruitment of patients from the emphasized populations.
• Clinical Research Sites must provide plans for accruing patients from diverse patient populations.

• Maximum funding of $7,200,000 for direct costs (plus indirect costs), including no less than $500,000 per year for support of two or more Affiliate Clinical Research Sites.
• Maximum period of performance is 4 years.

Clinical Sites:

• Maximum funding of $1,200,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.